Study of Subcutaneous Rehydration With Recombinant Human Hyaluronidase for Infants and Children

Pediatric patients (2 months to 10 years of age), presenting to the emergency department (ED) with mild to moderate dehydration and requiring parenteral rehydration, were treated with HYLENEX-augmented subcutaneous (SC) rehydration. An initial volume of 20 mL/kg of isotonic fluid was to be administered by continuous SC infusion over the first hour, and additional SC rehydration could be continued as clinically indicated. The preferred anatomic site for the SC infusion was the anterior thigh, unless there was an overriding preference for an alternate site.

The duration of HYLENEX-augmented SC rehydration was to be a minimum of 1 hour and a maximum of 72 hours. The investigator or designee performed a clinical assessment of the subject's hydration status at baseline and at the end of SC infusion or at discharge from the ED. Other assessments of effectiveness and safety were made directly during the rehydration period and ED stay, and by telephone on Days 3 and 7 after discharge from the ED.

Inclusion criteria

• Child, 2 months to 10 years of age
• Body weight less than 42 kg
• Presenting at emergency department with mild to moderate dehydration (Gorelick dehydration classification: presence of 1 to 6 [of possible 10] moderate or severe signs and symptoms) requiring parenteral rehydration

Exclusion criteria

• In shock or life-threatening situation (other than dehydration)
• Severe dehydration
• Requires intravenous (IV) therapy for another indication
• Indwelling IV catheter (excepting one intended strictly for clinical laboratory sample collection)
• Already received rehydration therapy IV within prior 48 hours or substantial oral fluid immediately before enrollment
• Condition precluding subcutaneous injection or infusion site evaluation in anterior thigh or other elected infusion site
• Reason for hospital admission or extended emergency department stay other than dehydration
• Known hypersensitivity to hyaluronidase or another ingredient in HYLENEX
• Hyponatremia or hypernatremia
• Hypokalemia
• Medical condition likely to interfere with ability to fully complete study or have protocol-specified assessments
• Medical history, screening examination finding or historical clinical laboratory result precluding safe participation in study or which might adversely effect interpretation of study results
• Participated in study of any investigational drug or device within 30 days prior to this study